BLENDS / BLEND
CJC-1295 NODAC 5MG + IPAMORELIN 5MG
10MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A 1:1 research blend pairing CJC-1295 (no DAC) with Ipamorelin, studied together in growth-hormone-axis signalling research.
Available Strengths
- 10MG (CP10)
Research Protocol
Reference gradual schedule (mcg figures below are per compound; volume/units reflect the combined draw)
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–2 (100 mcg each) | 0.1 mg | 3 | 0.03 mL |
| Weeks 3–4 (150 mcg each) | 0.15 mg | 4.5 | 0.045 mL |
| Weeks 5–6 (200 mcg each) | 0.2 mg | 6 | 0.06 mL |
| Weeks 7–12 (up to 300 mcg each) | 0.3 mg | 9 | 0.09 mL |
Reconstitution
≈3.33 mg/mL combined (≈1.67 mg/mL each compound); the schedule below uses the combined-vial concentration.
- Draw 3.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Component research describes CJC-1295 (no DAC) as a modified GHRH analogue and Ipamorelin as a selective growth-hormone secretagogue that avoids significant ACTH, cortisol or prolactin elevation; combined use is studied for a synergistic GH-axis effect.
Storage
−20°C, dry and dark. 2–8°C, use within ~28 days, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- There is no approved protocol for this proprietary combination.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source